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interleukin 6, the expression of which is also mod-
ulated by BMPR2.5 The currently enrolling clini-
cal trials in PAH with molecules such as FK506, 
rituximab, and anakinra selectively targeting the 
immune system are promising. In the study by 
Jasiewicz et al.,3 10 patients were incident cases 
who received PAH-targeted therapy at entry to 
the study. It would be interesting to see whether 
the levels of OPG and sRANKL changed in this 
group during the 6-month follow-up.
Finally, different subtypes of PAH are charac-
terized by different mechanisms and inflamma-
tory profiles. The development of PAH associat-
ed with congenital heart disease is triggered by 
mechanical overload of the pulmonary vessels re-
sulting from an increased flow through the pul-
monary circulation, while some molecular mech-
anisms are thought to be involved in the initia-
tion and progression of idiopathic PAH. Jasiewicz 
et al.3 did not report any significant differences 
in serum OPG and sRANKL concentrations be-
tween patients with idiopathic PAH, PAH associ-
ated with congenital heart disease, and PAH as-
sociated with connective tissue disease. Does it 
mean that their results can be generalized to the 
whole PAH population or maybe the numbers of 
study groups were too small to prove heteroge-
neity of OPG and RANKL levels in different PAH 
etiologies?
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To the Editor Pulmonary arterial hypertension 
(PAH) is characterized by perivascular inflamma-
tory infiltrates and elevated levels of certain cy-
tokines.1 These abnormalities are more advanced 
in patients with a mutation in the bone morpho-
genetic protein receptor type 2 (BMPR2), which 
significantly increases the risk of idiopathic PAH. 
The BMPR2 mutation has been reported in 11% 
to 40% of subjects with idiopathic PAH, while 
the dysfunction of the BMPR2 signaling path-
way has been observed in all types of PAH.2 As 
the expression of the receptor activator of nuclear 
factor-кB ligand (RANKL) is induced by BMPR2, 
a recent study by Jasiewicz et al.3 who investi-
gated the role of soluble RANKL (sRANKL) and 
its decoy receptor, osteoprotegerin (OPG), in pa-
tients with PAH is of particular importance.3 They 
showed that the levels of sRANKL and OPG were 
higher in patients with PAH compared with con-
trols and correlated with markers of disease se-
verity. However, the practical value of their re-
sults is still unclear.
Theoretically, some markers of inflammation 
specific for PAH could serve as screening tests for 
this disease in patients with unexplained breath-
lessness or in high-risk groups such as patients 
with connective tissue disease, congenital heart 
disease, portal hypertension, HIV infection, and 
others. Experimental pulmonary hypertension 
suggests that altered immunity is a cause rath-
er than consequence of vascular disease; there-
fore, early detection of PAH-specific inflamma-
tory changes could potentially enable the causal 
treatment of the disease.
The clinical effect of the modulation of the im-
mune system in patients with PAH by PAH-spe-
cific therapies (prostanoids, endothelin recep-
tor antagonists, and phosphodiesterase inhib-
itors) is poorly understood. Although the find-
ings from basic science studies are encourag-
ing, clinical studies show unequivocal results.4 
Recently, we have shown that a 3-month treat-
ment of patients with idiopathic PAH with specif-
ic therapies have not changed the plasma level of 
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